Federal Register / Vol. 89, No. 11 / Wednesday, January 17, 2024 / Notices 2967 

collection, the National Institute of 

Health is collecting audience feedback 

on a selection of survey questions and 

research protocols. Parents/caregivers 

and teens who are the same age as the 

study cohort members but who are not 

Study participants will review proposed 

questions and give feedback on 

questions’ clarity and acceptability. 

Recommendations from these findings 

help the ABCD Study team improve 

their protocol for a more-successful data 

collection. 

Audience feedback activities will 

include a mix of asynchronous and 

scheduled, live data collection: webbased survey activities, virtual 

discussion boards, individual 

interviews, and discussions groups. 

Assembling a cohort of audience 

feedback participants who are familiar 

with the ABCD Study and participate in 

multiple data collection activities 

minimizes the burden required to 

familiarize new participants with the 

purpose of the Study and the 

expectations for audience feedback. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

172. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Number of 

respondents 

Number of 

responses per 

respondent 

Average time 

per response 

(in hours) 

Total annual 

burden hour 

Individuals (Parent/Caregiver Phone Screener) .......................................... 72 1 5/60 6 

Individuals (Parent/Caregiver Consent) ....................................................... 15 1 5/60 1 

Individuals (Parent/Caregiver Permission for Teen Participation) ............... 36 1 5/60 3 

Individuals (Teen Phone Screener) ............................................................. 72 1 5/60 6 

Individuals (Teen Assent or Consent) ......................................................... 36 1 10/60 6 

Individuals (Teen Web Survey) ................................................................... 36 2 30/60 36 

Individuals (Parent/Caregiver Web Survey) ................................................ 15 2 30/60 15 

Individuals (Teen Virtual Group Discussion or Online Bulletin Board) ....... 36 2 1 72 

Individuals (Parent/Caregiver Virtual Interview) .......................................... 15 1 30/60 8 

Individuals (Parent/Caregiver Online Bulletin Board) .................................. 15 1 1 15 

Individuals (Parent/Caregiver ‘‘At-Home’’ Materials Review) ...................... 15 1 15/60 4 

Total ...................................................................................................... ........................ 450 .......................... 172 

Lanette A. Palmquist, 

Project Clearance Liaison, National Institute 

on Drug Abuse, National Institutes of Health. 

[FR Doc. 2024–00760 Filed 1–16–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2024–1 Phase I: Novel Diagnostic Biomarker 

Discovery and Validation for Malaria and 

Select Neglected Tropical Diseases (NTDs) 

(Topic 132). 

Date: February 15, 2024. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G13A, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Mairi Noverr, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G13A, Rockville, MD 

20852, (240) 747–7530, mairi.noverr@

nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Small Business Innovation 

Research (SBIR) Phase II Program Contract 

Solicitation (PHS 2022–1) Topic 108— 

Development of Rapid POC Diagnostics for 

Treponema pallidum (N01). 

Date: February 16, 2024. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G13A, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Mairi Noverr, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G13A, Rockville, MD 

20852, (240) 747–7530, mairi.noverr@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 11, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00773 Filed 1–16–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 


lotter on DSK11XQN23PROD with NOTICES1
2968 Federal Register / Vol. 89, No. 11 / Wednesday, January 17, 2024 / Notices 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2024–1 Phase I: Adjuvant Development for 

Vaccines for Infectious and ImmuneMediated Diseases (Topic 128). 

Date: February 8–9, 2024. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G22, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Michael M. Opata, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G22, Rockville, MD 

20852, 240–627–3319, michael.opata@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 11, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00774 Filed 1–16–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center For Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Surgical Sciences, 

Biomedical Imaging and Bioengineering 

Integrated Review Group; Surgery, 

Anesthesiology and Trauma Study Section. 

Date: February 7–8, 2024. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Weihua Luo, MD, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5114, 

MSC 7854, Bethesda, MD 20892, (301) 435– 

1170, luow@csr.nih.gov. 

Name of Committee: Brain Disorders and 

Clinical Neuroscience Integrated Review 

Group; Pathophysiological Basis of Mental 

Disorders and Addictions Study Section. 

Date: February 7–8, 2024. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Boris P. Sokolov, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5217A, 

MSC 7846, Bethesda, MD 20892, 301–408– 

9115, bsokolov@csr.nih.gov. 

Name of Committee: Surgical Sciences, 

Biomedical Imaging and Bioengineering 

Integrated Review Group; Imaging Probes and 

Contrast Agents Study Section. 

Date: February 8–9, 2024. 

Time: 7:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: DoubleTree McLean Tysons, 1960 

Chain Bridge Road, McLean, VA 22101. 

Contact Person: Donald Scott Wright, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5108, 

MSC 7854, Bethesda, MD 20892, (301) 435– 

8363, wrightds@csr.nih.gov. 

Name of Committee: Biological Chemistry 

and Macromolecular Biophysics Integrated 

Review Group; Macromolecular Structure 

and Function C Study Section. 

Date: February 8–9, 2024. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Bethesdan Hotel, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Guillermo Andres 

Bermejo, Ph.D., Scientific Review Officer, 

The Center for Scientific Review, The 

National Institutes of Health, 6701 Rockledge 

Drive, Bethesda, MD 20892, (301) 827–5742, 

bermejog@mail.nih.gov. 

Name of Committee: Biology of 

Development and Aging Integrated Review 

Group; Mechanisms of Cancer Therapeutics 

B Study Section. 

Date: February 8–9, 2024. 

Time: 8:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6705 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Maria Dolores Arjona 

Mayor, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 806D, Bethesda, MD 20892, (301) 827– 

8578, dolores.arjonamayor@nih.gov. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group; Sensory-Motor 

Neuroscience Study Section. 

Date: February 8–9, 2024. 

Time: 8:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency, Bethesda One, 

Bethesda Metro Center, Bethesda, MD 20814. 

Contact Person: Alena Valeryevna 

Savonenko, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 1009J, Bethesda, MD 20892, (301) 594– 

3444, savonenkoa2@csr.nih.gov. 

Name of Committee: Endocrinology, 

Metabolism, Nutrition and Reproductive 

Sciences Integrated Review Group; Basic 

Mechanisms of Diabetes and Metabolism 

Study Section. 

Date: February 8–9, 2024. 

Time: 8:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites—Old Town 

Alexandri,a Hilton Alexandria Old Town, VA 

22314. 

Contact Person: Baskaran Thyagarajan, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 800B, 

Bethesda, MD 20892, (301) 594–0331, 

BASKI.THYAGARAJAN@NIH.GOV, 

Name of Committee: Biobehavioral and 

Behavioral Processes Integrated Review 

Group; Language and Communication Study 

Section. 

Date: February 8–9, 2024. 

Time: 8:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Washington Plaza Hotel, 10 Thomas 

Circle NW, Washington, DC 20005. 

Contact Person: Rochelle Francine 

Hentges, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 1000C, Bethesda, MD 20892, (301) 

402–8720, hentgesrf@mail.nih.gov. 

Name of Committee: Population Sciences 

and Epidemiology Integrated Review Group; 

Kidney Endocrine and Digestive Disorders 

Study Section. 

Date: February 8–9, 2024. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Steven M. Frenk, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3141, 

Bethesda, MD 20892, (301) 480–8665, 

frenksm@mail.nih.gov. 

Name of Committee: Vascular and 

Hematology Integrated Review Group; 

Atherosclerosis and Vascular Inflammation 

Study Section. 

Date: February 8–9, 2024. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 


lotter on DSK11XQN23PROD with NOTICES1